Viewing nowSinubi Tablet 100 mg (Sitagliptin Hydrochloride Monohydrate)
Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.

MFDS item code 202100091 · Approved 2021.01.06 · Insurance code 647805590
Improvement of glycemic control in type 2 diabetes mellitus
This drug is used in conjunction with diet and exercise to help control blood sugar levels in patients with type 2 diabetes. It is initially administered as monotherapy, but if blood sugar control is insufficient, it may be used in combination with metformin. Additionally, this drug can be used to control blood sugar when mono-therapy with sulfonylureas, metformin, thiazolidinediones, or insulin is ineffective. In cases where blood sugar control remains challenging with combination therapy, this drug may be added to sulfonylureas and metformin or other combination regimens to enhance therapeutic effects. This drug is used to improve blood sugar control in patients with type 2 diabetes.
Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, section 5. General Precautions). Patients with renal impairment Because dosage adjustment based on renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.
This drug may cause severe allergic reactions in some patients. If symptoms such as skin rash, difficulty breathing, or swelling of the face or neck appear within the first 3 months of starting the medication, use should be discontinued immediately and a physician consulted. Additionally, this drug can cause severe side effects such as pancreatitis, which is an inflammation of the pancreas. If abdominal pain, vomiting, or severe abdominal pain occurs, immediate medical attention is required. Patients with type 1 diabetes, diabetic ketoacidosis, or known allergies to this drug or its components should not use it. Patients with impaired kidney function may require dosage adjustments, and regular kidney function tests are important. During treatment, symptoms similar to a cold, headache, indigestion, or diarrhea may occur. When used in conjunction with insulin or other glucose-lowering agents for diabetes treatment, there is a risk of hypoglycemia, so careful monitoring of blood sugar is essential. If severe joint pain or blistering on the skin occurs, immediate consultation with a doctor is necessary, and discontinuation of the drug may be required if these symptoms are suspected. It is not recommended for use during pregnancy or breastfeeding. In case of overdose, standard treatment should be rendered, and dialysis may be necessary as needed. Finally, regular medical checkups to monitor for side effects during the use of this drug are important.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in an airtight container and kept at room temperature (between 1 to 30 degrees Celsius). Proper storage will help maintain the drug's effectiveness over time.
Light orange, round, biconvex film-coated tablet
30 tablets/box [10 tablets/PTP x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.